Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity.

Head & Neck Pub Date : 2014-10-01 Epub Date: 2014-02-01 DOI:10.1002/hed.23487

Jianhua Xu, Xia He, Kong Cheng, Wenjie Guo, Xiuhua Bian, Xuesong Jiang, Lanfang Zhang, Shengfu Huang

{"title":"Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity.","authors":"Jianhua Xu, Xia He, Kong Cheng, Wenjie Guo, Xiuhua Bian, Xuesong Jiang, Lanfang Zhang, Shengfu Huang","doi":"10.1002/hed.23487","DOIUrl":null,"url":null,"abstract":"Background: The purpose of this study was to review the survival and toxicity in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiation therapy (IMRT) and concurrent nedaplatin plus paclitaxel or fluorouracil (NP or NF).Methods: A total of 155 patients with locoregionally advanced NPC seen at our institution between January 2008 and December 2010 were retrospectively reviewed. Seventy-nine cases (51%) were treated with IMRT and concurrent NP chemotherapy, and 76 cases (49%) were treated with IMRT and concurrent NF regimen. Survival and toxicity were reported.Results: The 3-year locoregional relapse-free survival, distant metastasis-free survival, progression-free survival (PFS), and overall survival (OS) rates were 90.3% and 87.8%, 79.7% and 81.1%, 77.3% and 71.1%, and 81.6% and 83.7% for the NF and NP group, respectively. The results were comparable to that of the cisplatin-based regimens. Acute and late toxicities were acceptable.Conclusion: IMRT with concurrent nedaplatin-based chemotherapy achieved comparable survival with acceptable toxicity to those of the cisplatin-based regimens in the treatment of locoregionally advanced NPC.","PeriodicalId":501638,"journal":{"name":"Head & Neck","volume":" ","pages":"1474-80"},"PeriodicalIF":0.0000,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hed.23487","citationCount":"21","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head & Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.23487","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/2/1 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 21

Abstract

Background: The purpose of this study was to review the survival and toxicity in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiation therapy (IMRT) and concurrent nedaplatin plus paclitaxel or fluorouracil (NP or NF).

Methods: A total of 155 patients with locoregionally advanced NPC seen at our institution between January 2008 and December 2010 were retrospectively reviewed. Seventy-nine cases (51%) were treated with IMRT and concurrent NP chemotherapy, and 76 cases (49%) were treated with IMRT and concurrent NF regimen. Survival and toxicity were reported.

Results: The 3-year locoregional relapse-free survival, distant metastasis-free survival, progression-free survival (PFS), and overall survival (OS) rates were 90.3% and 87.8%, 79.7% and 81.1%, 77.3% and 71.1%, and 81.6% and 83.7% for the NF and NP group, respectively. The results were comparable to that of the cisplatin-based regimens. Acute and late toxicities were acceptable.

Conclusion: IMRT with concurrent nedaplatin-based chemotherapy achieved comparable survival with acceptable toxicity to those of the cisplatin-based regimens in the treatment of locoregionally advanced NPC.

查看原文本刊更多论文

奈达铂联合紫杉醇或氟尿嘧啶同步放化疗治疗局部进展期鼻咽癌:生存和毒性

背景:本研究的目的是回顾调强放疗(IMRT)和奈达铂联合紫杉醇或氟尿嘧啶(NP或NF)治疗局部晚期鼻咽癌(NPC)患者的生存和毒性。方法:回顾性分析2008年1月至2010年12月我院收治的155例局部晚期鼻咽癌患者。IMRT联合NP化疗79例(51%)，IMRT联合NF化疗76例(49%)。报告了存活率和毒性。结果:NF组和NP组3年局部无复发生存率、远处无转移生存率、无进展生存率(PFS)和总生存率(OS)分别为90.3%和87.8%、79.7%和81.1%、77.3%和71.1%、81.6%和83.7%。结果与以顺铂为基础的方案相当。急性和晚期毒性是可以接受的。结论:与以顺铂为基础的方案相比，IMRT联合以奈达铂为基础的化疗在治疗局部区域晚期鼻咽癌方面取得了相当的生存期和可接受的毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head & Neck

自引率

0.00%

发文量